A Phase 3 interventional study of Guselkumab and Placebo for guselkumab in Psoriasis, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 39 sites in 9 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.
Among the 29 studies testing guselkumab in Psoriasis, this one is the 15th largest by enrollment, is one of 2 that started in 2018, is one of 12 in phase 3, and was the 12th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Fondazione Policlinico Universitario Campus Bio-Medico · Sites in Italy
Ages 18–80
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 120 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
76 studies in Psoriasis by Johnson & Johnson: 3 open now, 12 under way, 7 of them phase 3. Of 64 finished, 33 (52%) have results posted.
Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 37th largest by enrollment of the 58 interventional ones that give a count, is the only one that started in 2018, is one of 36 in phase 3, reaches primary completion later than 0 of the 11 other live ones, and was the 53rd registered.
Johnson & Johnson’s Psoriasis studies by the year they started, since 2002.
3 of the studies testing guselkumab in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004727NYU Langone HealthMulti-Center PAMPA Study | 2026-12-31 |
| NCT07532486Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis | 2027-07-10 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies testing guselkumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 76 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Part 1a (age greater than or equal to (\>=) 12 - less than (\<) 18 years) will receive a weight-based dose of guselkumab subcutaneously (SC) at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of guselkumab until they lose \>=50% of their Week 16 PASI response, then they receive 1 dose guselkumab, followed by a dose 4 weeks later, and every 8 weeks (q8w) thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a placebo injection at Week 16 and continue to receive guselkumab q8w from Week 20 through Week 52. Participants who are eligible and willing to continue guselkumab may enter the Long Term Extension (LTE) Phase of the study. Part 1b (age \>= 6 - \<12 years) will follow the same dosing and commence after Part 1a data review.
Drug: Guselkumab · Drug: Placebo for guselkumab
Participants in Part 1a (age \>= 12 - \<18 years) will receive placebo for guselkumab administered SC at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of study intervention until they lose \>=50% of their Week 16 PASI response, at which time they will receive a weight-based guselkumab SC dose, followed by a dose 4 weeks later, and q8w thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a weight-based guselkumab dose at Weeks 16 and 20, followed by q8w dosing thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE phase of the study. Part 1b (age \>= 6 - \<12 years) will follow the same dosing and commence after Part 1a data review.
Drug: Guselkumab · Drug: Placebo for guselkumab
Participants in Part 1a (age \>= 12 - \<18 years) will receive weight-based etanercept dose up to 50 milligram SC weekly through Week 15. Participants who elect to continue in the study will receive a weight-based guselkumab dose at Weeks 20 and 24, followed by q8w dosing thereafter through Week 48. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE phase of the study. Part 1b (age \>= 6 - \<12 years) will follow the same dosing and commence after Part 1a data review.
Drug: Guselkumab · Drug: Etanercept
Participants will receive a weight-based dose of open-label guselkumab SC at Weeks 0, 4 and q8w thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab at Week 52 and q8w thereafter.
Drug: Guselkumab
Participants will receive a weight-based dose of guselkumab subcutaneously.
Also known as: CNTO1959
Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.
Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.
Also known as: Enbrel
Part 1: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
Time frame: At Week 16
Part 1: Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 75 response represented participants who achieved at least a 75 % improvement from baseline in the PASI score.
Time frame: At Week 16
Part 1: Percentage of Participants Who Achieve PASI 90 Response at Week 16
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 90 response represented participants who achieved at least a 90 % improvement from baseline in the PASI score.
Time frame: At Week 16
Part 1: Percentage of Participants Who Achieved an IGA Score of Cleared (0) at Week 16
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
Time frame: At Week 16
Part 1: Percentage of Participants Who Achieved PASI 100 Response at Week 16
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 100 response represented participants who achieved a 100 % improvement from baseline in the PASI score.
Time frame: At Week 16
Part 1: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Score at Week 16
CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of questions 1-10 and ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children. Change from baseline is defined as post baseline score minus baseline score.
Time frame: Baseline and Week 16
Part 1: Percentage of Retreated Participants Who Achieved a PASI 90 Response Over Time After Retreatment
PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 90 response represented participants who achieved at least a 90 % improvement from baseline in PASI score.
Time frame: At 4 and 8 weeks post retreatment (retreatment period ranged from Week 16 to Week 52)
Part 1: Percentage of Retreated Participants Who Achieved PASI Responses (PASI 50, 75, 90, and 100) Over Time After Retreatment
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease. PASI 50, 75, 90 and 100 response represented at least 50, 75, 90 and 100% improvement from baseline respectively, in the PASI score.
Time frame: At 4 and 8 weeks post retreatment (retreatment period ranged from Week 16 to Week 52)
Part 1: Percentage of Retreated Participants Who Achieved IGA Responses (IGA of Cleared [0], Minimal [1], or Mild [2], IGA of Cleared [0] or Minimal [1], and IGA of Cleared [0]) Over Time After Retreatment
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 points scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 points scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
Time frame: At 4 and 8 weeks post retreatment (retreatment period ranged from Week 16 to Week 52)
Part 1: Cumulative Rate of Loss of at Least 50% of Week 16 PASI Improvement Through Week 52 Among Guselkumab PASI 90 Responders at Week 16
Cumulative rate of loss of at least 50% of PASI improvement was defined as percentage of participants with a loss of \>=50% of Week 16 PASI improvement after treatment is withdrawn. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease.
Time frame: Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52
Part 1: Cumulative Maintenance Rate of PASI 90 Response Through Week 52 Among Guselkumab PASI 90 Responders at Week 16
Cumulative maintenance rate was defined as percentage of participants who maintained their PASI 90 response through Week 52 among guselkumab PASI 90 responders at Week 16. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 90 response represented participants who achieved at least a 90% improvement from baseline in PASI score.
Time frame: Week 20, 24, 28, 32, 36, 40, 44, 48, and 52
Part 1: Percentage of Participants Who Achieved a PASI 50 Response at Week 16
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 50 response represented at least a 50% improvement from baseline in the PASI score.
Time frame: At Week 16
Part 1: Percent Improvement From Baseline in PASI Through Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease.
Time frame: Weeks 4, 8, 12, and 16
Part 2: Percent Improvement From Baseline in PASI Through Week 52
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease.
Time frame: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52
Part 1: Percentage of Participants With PASI Responses (PASI 50, 75, 90, and 100) Through Week 16
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease. PASI 50, 75, 90, and 100 responses represented at least 50%, 75%, 90%, and 100% improvement from baseline respectively, in the PASI score.
Time frame: Weeks 4, 8, 12, and 16
Part 2: Percentage of Participants With PASI Responses (PASI 50, 75, 90, and 100) Through Week 52
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease. PASI 50, 75, 90, and 100 responses represented at least 50%, 75%, 90%, and 100% improvement from baseline respectively, in the PASI score.
Time frame: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52
Part 1: Percentage of Participants With IGA of Cleared (0), Cleared (0) or Minimal (1), Mild or Better (<=2) Through Week 16
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 points scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 points scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
Time frame: Weeks 4, 8, 12, and 16
Part 2: Percentage of Participants With IGA of Cleared (0), Cleared (0) or Minimal (1), Mild or Better (<=2) Through Week 52
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 points scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 points scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
Time frame: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52
Part 2: Change From Baseline in CDLQI Score Through Week 52
Change from baseline in CDLQI score through Week 52 were reported. CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of questions 1-10 and ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.
Time frame: Baseline, Weeks 8, 16, 28, 36, and 52
Part 1: Percentage of Participants With CDLQI Score Equal to 0 or 1 at Week 16 Among Participants With a Baseline CDLQI Score Greater Than (>) 1
CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of question 1-10 and ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.
Time frame: At Week 16
Part 2: Percentage of Participants With CDLQI Score Equal to of 0 or 1 Through Week 52 Among Participants With a Baseline CDLQI Score > 1
CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of question 1-10 and ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.
Time frame: Weeks 8, 16, 28, 36, and 52
Part 1: Percentage of Participants With Family Dermatology Life Quality Index (FDLQI) of 0 or 1 at Week 16 Among Participants With a Baseline FDLQI >1
The FDLQI was a 10-item questionnaire that examined the impact of participant's skin disease on different aspects of their QoL (example: emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) were added to give a total scale score that ranged from 0 to 30; a higher score indicated greater impairment of QoL.
Time frame: At Week 16
Part 2: Percentage of Participants With Family Dermatology Life Quality Index (FDLQI) of 0 or 1 Through Week 52 Among Participants With a Baseline FDLQI >1
The FDLQI was a 10-item questionnaire that examine the impact of participant's skin disease on different aspects of their QoL (example, emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) were added to give a total scale score that ranged from 0 to 30; a higher score indicates greater impairment of QoL.
Time frame: Weeks 8, 16, 28, 36, and 52
Part 1: Change From Baseline in FDLQI Score at Week 16
The FDLQI was a 10-item questionnaire that examined the impact of participant's skin disease on different aspects of their QoL (example, emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) are added to give a total scale score that ranged from 0 to 30; a higher score indicates greater impairment of QoL.
Time frame: Baseline and Week 16
Part 2: Change From Baseline in FDLQI Score Through Week 52
The FDLQI was a 10-item questionnaire that examine the impact of participant's skin disease on different aspects of their QoL (example, emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) are added to give a total scale score that ranged from 0 to 30; a higher score indicated greater impairment of QoL.
Time frame: Baseline, Weeks 8, 16, 28, 36, and 52
Part 1: Change From Baseline in Body Surface Area (BSA) With Psoriasis Skin Involvement at Week 16
Change from baseline in percent body surface area with psoriasis skin involvement was reported. BSA as physical measure to define disease severity is to determine how much of the BSA is affected by psoriasis. Involved BSA is calculated by using the palm of the participant's hand as equivalent to 1% of the BSA (rule of palm). Psoriasis affected BSA under 5% suggests mild psoriasis, a BSA of 5% to 10% is considered moderate, and an involved BSA of over 10% indicates severe psoriasis.
Time frame: Baseline and Week 16
Parts 2: Change From Baseline in BSA With Psoriasis Skin Involvement Over Time Through Week 52
Change from baseline in percent body surface area with psoriasis skin involvement was reported. BSA as physical measure to define disease severity is to determine how much of the BSA is affected by psoriasis. Involved BSA is calculated by using the palm of the participant's hand as equivalent to 1% of the BSA (rule of palm). Psoriasis affected BSA under 5% suggests mild psoriasis, a BSA of 5% to 10% is considered moderate, and an involved BSA of over 10% indicates severe psoriasis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52
LTE Phase: Percentage of Participants Who Achieved PASI Responses (PASI 50, 75, 90, and 100) Over Time
Time frame: From Week 52 to End of the study (EOS) (December 2026)
LTE Phase: Percentage of Participants Who Achieved IGA Score of (Cleared [0], Cleared [0] or Minimal [1], Mild or Better [<=2] Over Time
Time frame: From Week 52 to EOS (December 2026)
LTE Phase: Percent Improvement From Baseline in PASI Over Time
Time frame: From Week 52 to EOS (December 2026)
LTE Phase: Change From Baseline in BSA With Psoriasis Skin Involvement Over Time
Time frame: From Week 52 to EOS (Dec 2026)
LTE Phase: Percentage of Participants Who Achieved PASI Responses (PASI 50, 75, 90,and 100) at Weeks 60 and 84 After Retreatment Among Guselkumab Participants Who Were Withdrawn From Guselkumab at Week 16 and Retreated Upon Loss of Response or at Week 52
Time frame: Week 60 and Week 84
LTE Phase: Percentage of Participants Who Achieved IGA Score of (Cleared [0], Cleared [0] or Minimal [1], Mild or Better [<=2] at Weeks 60 and 84 After Retreatment
Time frame: Week 60 and Week 84
LTE Phase: Percent Improvement in PASI Responses (PASI 50, 75, 90, and 100) at Weeks 60 and 84 After Retreatment Among Guselkumab Subjects Who Were Withdrawn From Guselkumab at Week 16 and Subsequently Retreated Upon Loss of Response or at Week 52
Time frame: Week 60 and Week 84
LTE Phase: Change From Baseline in BSA at Weeks 60 and 84 After Retreatment Among Guselkumab Subjects Who Were Withdrawn From Guselkumab at Week 16 and Subsequently Retreated Upon Loss of Response or at Week 52
Time frame: Week 60 and Week 84
| Milestone | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) | Group 1 (Part 1): Placebo to Guselkumab (Week 16-52) | Group 2 (Part 1): Guselkumab (Week 16-52) | Group 3 (Part 1): Etanercept to Guselkumab (Week 16-52) | Part 2: Guselkumab (Week 0-16) | Part 2: Guselkumab (Week 16-52) |
|---|---|---|---|---|---|---|---|---|
| Started | 25 | 41 | 26 | 0 | 0 | 0 | 28 | 0 |
| Completed | 24 | 41 | 23 | 0 | 0 | 0 | 27 | 0 |
| Not completed | 1 | 0 | 3 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) | Group 1 (Part 1): Placebo to Guselkumab (Week 16-52) | Group 2 (Part 1): Guselkumab (Week 16-52) | Group 3 (Part 1): Etanercept to Guselkumab (Week 16-52) | Part 2: Guselkumab (Week 0-16) | Part 2: Guselkumab (Week 16-52) |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 23 | 41 | 22 | 0 | 27 |
| Completed | 0 | 0 | 0 | 23 | 35 | 21 | 0 | 27 |
| Not completed | 0 | 0 | 0 | 0 | 6 | 1 | 0 | 0 |
| Withdrew: Other withdrawal by parent/guardian | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 |
| Withdrew: Other unspecified | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other- completed safety follow up | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
| Percentages of participants | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Part 1: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 | 16.0 | 65.9 | 69.2 |
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 75 response represented participants who achieved at least a 75 % improvement from baseline in the PASI score.
| Percentage of Participants | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Part 1: Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16 | 20.0 | 75.6 | 69.2 |
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 90 response represented participants who achieved at least a 90 % improvement from baseline in the PASI score.
| Percentage of Participants | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Part 1: Percentage of Participants Who Achieve PASI 90 Response at Week 16 | 16.0 | 56.1 | 53.8 |
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
| Percentages of participants | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Part 1: Percentage of Participants Who Achieved an IGA Score of Cleared (0) at Week 16 | 4.0 | 39.0 | 26.9 |
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 100 response represented participants who achieved a 100 % improvement from baseline in the PASI score.
| Percentages of participants | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Part 1: Percentage of Participants Who Achieved PASI 100 Response at Week 16 | 0 | 34.1 | 26.9 |
CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of questions 1-10 and ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children. Change from baseline is defined as post baseline score minus baseline score.
| Score on a scale | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Part 1: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Score at Week 16 | -1.68 ± 6.323 | -7.12 ± 7.633 | -6.08 ± 5.692 |
PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 90 response represented participants who achieved at least a 90 % improvement from baseline in PASI score.
| Percentages of participants | Group 2 (Part 1): Guselkumab (Week 16-52) |
|---|---|
| 4 weeks after retreatment of guselkumab | 0 |
| 8 weeks after retreatment of guselkumab | 50.0 |
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease. PASI 50, 75, 90 and 100 response represented at least 50, 75, 90 and 100% improvement from baseline respectively, in the PASI score.
| At 4 and 8 weeks post retreatment | Group 2 (Part 1): Guselkumab (Week 16-52) |
|---|---|
| 4 weeks after retreatment: >=50% improvement | 50.0 |
| 4 weeks after retreatment: >=75% improvement | 0 |
| 4 weeks after retreatment:>= 90% improvement | 0 |
| 4 weeks after retreatment: 100% improvement | 0 |
| 8 weeks after retreatment: >=50% improvement | 50.0 |
| 8 weeks after retreatment: >=75% improvement | 50.0 |
| 8 weeks after retreatment:>= 90% improvement | 50.0 |
| 8 weeks after retreatment: 100% improvement | 50.0 |
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 points scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 points scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
| Percentages of participants | Group 2 (Part 1): Guselkumab (Week 16-52) |
|---|---|
| 4 Weeks after retreatment: IGA-0 | 0 |
| 4 Weeks after retreatment: IGA-0 or 1 | 25.0 |
| 4 Weeks after retreatment: IGA-2 | 75.0 |
| 8 Weeks after retreatment: IGA-0 | 50.0 |
| 8 Weeks after retreatment: IGA-0 or 1 | 50.0 |
| 8 Weeks after retreatment: IGA- 2 | 100.0 |
Cumulative rate of loss of at least 50% of PASI improvement was defined as percentage of participants with a loss of \>=50% of Week 16 PASI improvement after treatment is withdrawn. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease.
| Percentage of Participants | Group 2 (Part 1): Guselkumab (Week 16-52) |
|---|---|
| Week 20 | 0 |
| Week 24 | 0 |
| Week 28 | 0 |
| Week 32 | 0 |
| Week 36 | 0 |
| Week 40 | 0 |
| Week 44 | 9.3 |
| Week 48 | 19.1 |
| Week 52 | 19.1 |
Cumulative maintenance rate was defined as percentage of participants who maintained their PASI 90 response through Week 52 among guselkumab PASI 90 responders at Week 16. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 90 response represented participants who achieved at least a 90% improvement from baseline in PASI score.
| Percentage of participants | Group 2 (Part 1): Guselkumab (Week 16-52) |
|---|---|
| Week 20 | 100 |
| Week 24 | 100 |
| Week 28 | 86.7 |
| Week 32 | 77.5 |
| Week 36 | 63.9 |
| Week 40 | 50.2 |
| Week 44 | 35.8 |
| Week 48 | 30.7 |
| Week 52 | 25.6 |
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 % to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe). The PASI produced a numeric score that can range from 0 (no visible skin involvement) to 72 (maximal skin involvement of the whole body). A higher score indicated more severe disease. A PASI 50 response represented at least a 50% improvement from baseline in the PASI score.
| Percentages of participants | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Part 1: Percentage of Participants Who Achieved a PASI 50 Response at Week 16 | 28.0 | 87.8 | 76.9 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease.
| Percent improvement | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Week 4 | 13.37 ± 30.074 | 39.12 ± 27.907 | 42.53 ± 26.013 |
| Week 8 | 13.61 ± 40.734 | 71.25 ± 28.018 | 64.27 ± 29.314 |
| Week 12 | 13.67 ± 52.391 | 79.79 ± 28.570 | 77.30 ± 24.735 |
| Week 16 | 16.02 ± 55.538 | 79.83 ± 30.468 | 82.05 ± 23.225 |
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease.
| Percent improvement | Part 2: Guselkumab (Week 0-52) |
|---|---|
| Week 4 | 48.33 ± 26.781 |
| Week 8 | 79.05 ± 21.177 |
| Week 12 | 86.40 ± 15.541 |
| Week 16 | 91.96 ± 11.177 |
| Week 20 | 91.10 ± 14.851 |
| Week 28 | 93.44 ± 12.948 |
| Week 36 | 95.77 ± 7.848 |
| Week 44 | 95.95 ± 7.430 |
| Week 52 | 96.32 ± 7.478 |
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease. PASI 50, 75, 90, and 100 responses represented at least 50%, 75%, 90%, and 100% improvement from baseline respectively, in the PASI score.
| Percentages of participants | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Week 4: >= 50% improvement | 8.0 | 34.1 | 38.5 |
| Week 4: >= 75% improvement | 8.0 | 12.2 | 15.4 |
| Week 4: >= 90% improvement | 4.0 | 2.4 | 3.8 |
| Week 4: 100% improvement | 0 | 0 | 0 |
| Week 8: >= 50% improvement | 20.0 | 78.0 | 73.1 |
| Week 8: >= 75% improvement | 8.0 | 51.2 | 46.2 |
| Week 8: >= 90% improvement | 4.0 | 34.1 | 19.2 |
| Week 8: 100% improvement | 4.0 | 12.2 | 11.5 |
| Week 12: >= 50% improvement | 24.0 | 85.4 | 76.9 |
| Week 12: >= 75% improvement | 12.0 | 73.2 | 61.5 |
| Week 12: >= 90% improvement | 8.0 | 56.1 | 38.5 |
| Week 12: 100% improvement | 0 | 34.1 | 26.9 |
| Week 16: >= 50% improvement | 28.0 | 87.8 | 76.9 |
| Week 16: >= 75% improvement | 20.0 | 75.6 | 69.2 |
| Week 16: >= 90% improvement | 16.0 | 56.1 | 53.8 |
| Week 16: 100% improvement | 0 | 34.1 | 26.9 |
The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produced a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicated more severe disease. PASI 50, 75, 90, and 100 responses represented at least 50%, 75%, 90%, and 100% improvement from baseline respectively, in the PASI score.
| Percentages of participants | Part 2: Guselkumab (Week 0-52) |
|---|---|
| Week 4: >= 50% improvement | 42.9 |
| Week 4: >= 75% improvement | 14.3 |
| Week 4: >= 90% improvement | 14.3 |
| Week 4: 100% improvement | 3.6 |
| Week 8: >= 50% improvement | 89.3 |
| Week 8: >= 75% improvement | 67.9 |
| Week 8: >= 90% improvement | 39.3 |
| Week 8: 100% improvement | 17.9 |
| Week 12: >= 50% improvement | 96.4 |
| Week 12: >= 75% improvement | 75.0 |
| Week 12: >= 90% improvement | 42.9 |
| Week 12: 100% improvement | 25.0 |
| Week 16: >= 50% improvement | 92.9 |
| Week 16: >= 75% improvement | 82.1 |
| Week 16: >= 90% improvement | 64.3 |
| Week 16: 100% improvement | 35.7 |
| Week 20: >= 50% improvement | 92.9 |
| Week 20: >= 75% improvement | 82.1 |
| Week 20: >= 90% improvement | 75.0 |
| Week 20: 100% improvement | 39.3 |
| Week 28: >= 50% improvement | 92.9 |
| Week 28: >= 75% improvement | 89.3 |
| Week 28: >= 90% improvement | 75.0 |
| Week 28: 100% improvement | 46.4 |
| Week 36: >= 50% improvement | 96.4 |
| Week 36: >= 75% improvement | 89.3 |
| Week 36: >= 90% improvement | 82.1 |
| Week 36: 100% improvement | 53.6 |
| Week 44: >= 50% improvement | 96.4 |
| Week 44: >= 75% improvement | 89.3 |
| Week 44: >= 90% improvement | 82.1 |
| Week 44: 100% improvement | 53.6 |
| Week 52: >= 50% improvement | 96.4 |
| Week 52: >= 75% improvement | 92.9 |
| Week 52: >= 90% improvement | 82.1 |
| Week 52: 100% improvement | 53.6 |
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 points scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 points scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
| Percentages of participants | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Week 4 : IGA of cleared (0) | 0 | 0 | 0 |
| Week 4 : IGA of cleared (0) or minimal (1) | 8.0 | 19.5 | 23.1 |
| Week 4 :IGA of mild or better (<=2) | 20.0 | 63.4 | 73.1 |
| Week 8: IGA of cleared (0) | 4.0 | 22.0 | 11.5 |
| Week 8 : IGA of cleared (0) or minimal (1) | 8.0 | 58.5 | 50.0 |
| Week 8 :IGA of mild or better (<=2) | 24.0 | 78.0 | 88.5 |
| Week 12: IGA of cleared (0) | 4.0 | 43.9 | 26.9 |
| Week 12 : IGA of cleared (0) or minimal (1) | 8.0 | 70.7 | 65.4 |
| Week 12 :IGA of mild or better (<=2) | 40.0 | 87.8 | 84.6 |
| Week 16: IGA of cleared (0) | 4.0 | 39.0 | 26.9 |
| Week 16 : IGA of cleared (0) or minimal (1) | 16.0 | 65.9 | 69.2 |
| Week 16 :IGA of mild or better (<=2) | 48.0 | 92.7 | 84.6 |
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 points scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 points scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
| Percentages of participants | Part 2: Guselkumab (Week 0-52) |
|---|---|
| Week 4: IGA of cleared (0) | 3.6 |
| Week 4: IGA of cleared (0) or minimal (1) | 25.0 |
| Week 4:IGA of mild or better (<=2) | 57.1 |
| Week 8: IGA of cleared (0) | 25.0 |
| Week 8: IGA of cleared (0) or minimal (1) | 64.3 |
| Week 8:IGA of mild or better (<=2) | 92.9 |
| Week 12: IGA of cleared (0) | 35.7 |
| Week 12: IGA of cleared (0) or minimal (1) | 75.0 |
| Week 12:IGA of mild or better (<=2) | 96.4 |
| Week 16: IGA of cleared (0) | 46.4 |
| Week 16: IGA of cleared (0) or minimal (1) | 89.3 |
| Week 16:IGA of mild or better (<=2) | 92.9 |
| Week 20: IGA of cleared (0) | 50.0 |
| Week 20: IGA of cleared (0) or minimal (1) | 82.1 |
| Week 20:IGA of mild or better (<=2) | 96.4 |
| Week 28: IGA of cleared (0) | 57.1 |
| Week 28: IGA of cleared (0) or minimal (1) | 78.6 |
| Week 28:IGA of mild or better (<=2) | 96.4 |
| Week 36: IGA of cleared (0) | 64.3 |
| Week 36: IGA of cleared (0) or minimal (1) | 89.3 |
| Week 36:IGA of mild or better (<=2) | 89.3 |
| Week 44: IGA of cleared (0) | 64.3 |
| Week 44: IGA of cleared (0) or minimal (1) | 85.7 |
| Week 44: IGA of mild or better (<=2) | 89.3 |
| Week 52: IGA of cleared (0) | 75.0 |
| Week 52: IGA of cleared (0) or minimal (1) | 85.7 |
| Week 52: IGA of mild or better (<=2) | 92.9 |
Change from baseline in CDLQI score through Week 52 were reported. CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of questions 1-10 and ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.
| Score on a scale | Part 2: Guselkumab (Week 0-52) |
|---|---|
| Week 8 | -5.6 ± 6.40 |
| Week 16 | -6.8 ± 6.32 |
| Week 28 | -6.7 ± 6.54 |
| Week 36 | -7.0 ± 6.88 |
| Week 52 | -7.3 ± 6.83 |
CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of question 1-10 and ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.
| Percentages of participants | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Part 1: Percentage of Participants With CDLQI Score Equal to 0 or 1 at Week 16 Among Participants With a Baseline CDLQI Score Greater Than (>) 1 | 17.4 | 64.1 | 38.5 |
CDLQI is a 10-item questionnaire that measures the impact of skin disease on children's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. CDLQI total score was the sum of individual scores of question 1-10 and ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.
| Percentages of participants | Part 2: Guselkumab (Week 0-52) |
|---|---|
| Week 8 | 50.0 |
| Week 16 | 58.3 |
| Week 28 | 66.7 |
| Week 36 | 62.5 |
| Week 52 | 66.7 |
The FDLQI was a 10-item questionnaire that examined the impact of participant's skin disease on different aspects of their QoL (example: emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) were added to give a total scale score that ranged from 0 to 30; a higher score indicated greater impairment of QoL.
| Percentages of participants | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Part 1: Percentage of Participants With Family Dermatology Life Quality Index (FDLQI) of 0 or 1 at Week 16 Among Participants With a Baseline FDLQI >1 | 13.0 | 36.1 | 24.0 |
The FDLQI was a 10-item questionnaire that examine the impact of participant's skin disease on different aspects of their QoL (example, emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) were added to give a total scale score that ranged from 0 to 30; a higher score indicates greater impairment of QoL.
| Percentages of participants | Part 2: Guselkumab (Week 0-52) |
|---|---|
| Week 8 | 27.3 |
| Week 16 | 31.8 |
| Week 28 | 59.1 |
| Week 36 | 36.4 |
| Week 52 | 50.0 |
The FDLQI was a 10-item questionnaire that examined the impact of participant's skin disease on different aspects of their QoL (example, emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) are added to give a total scale score that ranged from 0 to 30; a higher score indicates greater impairment of QoL.
| Score on a scale | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Part 1: Change From Baseline in FDLQI Score at Week 16 | -0.50 ± 6.984 | -6.22 ± 6.299 | -6.22 ± 4.814 |
The FDLQI was a 10-item questionnaire that examine the impact of participant's skin disease on different aspects of their QoL (example, emotional, physical well-being, relationships, social life, leisure activities, burden of care, job/study, housework and expenditure) over the last 1 month, as assessed by a family member/partner. Each item had a four-point response option, where Not at all/Not relevant = 0; A little = 1; Quite a lot = 2; and Very much = 3. The scores of individual items (0-3) are added to give a total scale score that ranged from 0 to 30; a higher score indicated greater impairment of QoL.
| Score on scale | Part 2: Guselkumab (Week 0-52) |
|---|---|
| Week 8 | -5.4 ± 5.58 |
| Week 16 | -5.5 ± 5.90 |
| Week 28 | -7.5 ± 6.15 |
| Week 36 | -6.7 ± 5.00 |
| Week 52 | -7.8 ± 5.68 |
Change from baseline in percent body surface area with psoriasis skin involvement was reported. BSA as physical measure to define disease severity is to determine how much of the BSA is affected by psoriasis. Involved BSA is calculated by using the palm of the participant's hand as equivalent to 1% of the BSA (rule of palm). Psoriasis affected BSA under 5% suggests mild psoriasis, a BSA of 5% to 10% is considered moderate, and an involved BSA of over 10% indicates severe psoriasis.
| Units on a scale | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) |
|---|---|---|---|
| Part 1: Change From Baseline in Body Surface Area (BSA) With Psoriasis Skin Involvement at Week 16 | -2.84 ± 13.861 | -19.59 ± 17.645 | -17.50 ± 10.628 |
Change from baseline in percent body surface area with psoriasis skin involvement was reported. BSA as physical measure to define disease severity is to determine how much of the BSA is affected by psoriasis. Involved BSA is calculated by using the palm of the participant's hand as equivalent to 1% of the BSA (rule of palm). Psoriasis affected BSA under 5% suggests mild psoriasis, a BSA of 5% to 10% is considered moderate, and an involved BSA of over 10% indicates severe psoriasis.
| Units on a scale | Part 2: Guselkumab (Week 0-52) |
|---|---|
| Week 4 | -6.9 ± 7.94 |
| Week 8 | -16.8 ± 12.00 |
| Week 12 | -19.6 ± 12.58 |
| Week 16 | -22.7 ± 13.57 |
| Week 20 | -24.0 ± 13.46 |
| Week 28 | -26.0 ± 14.61 |
| Week 36 | -26.3 ± 14.42 |
| Week 44 | -26.5 ± 14.05 |
| Week 52 | -26.4 ± 14.52 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over PCP (Part 1): Week 0 to 16; Withdrawal and re-treatment period (Part 1): Week 16 to 52; Part 2: Week 0 to 52. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PCP-Group 1 (Part 1): Placebo (Week 0-16) | 0/25 (0%) | 0/25 (0%) | 17/25 (68%) |
| PCP-Group 2 (Part 1): Guselkumab (Week 0-16) | 0/41 (0%) | 1/41 (2.4%) | 17/41 (41.5%) |
| PCP-Group 3 (Part 1): Etanercept (Week 0-16) | 0/26 (0%) | 0/26 (0%) | 15/26 (57.7%) |
| Withdrawal and Re-treatment Period-Group 1 (Part 1): Placebo to Guselkumab (Week 16-52) | 0/23 (0%) | 1/23 (4.3%) | 16/23 (69.6%) |
| Withdrawal and Re-treatment Period-Group 2 (Part 1): Guselkumab (Week 16-52) | 0/41 (0%) | 0/41 (0%) | 29/41 (70.7%) |
| Withdrawal and Re-treatment Period- Group 3 (Part 1): Etanercept to Guselkumab (Week 16-52) | 0/22 (0%) | 0/22 (0%) | 13/22 (59.1%) |
| Part 2: Guselkumab (Week 0-52) | 0/28 (0%) | 1/28 (3.6%) | 23/28 (82.1%) |
| Event | PCP-Group 1 (Part 1): Placebo (Week 0-16) | PCP-Group 2 (Part 1): Guselkumab (Week 0-16) | PCP-Group 3 (Part 1): Etanercept (Week 0-16) | Withdrawal and Re-treatment Period-Group 1 (Part 1): Placebo to Guselkumab (Week 16-52) | Withdrawal and Re-treatment Period-Group 2 (Part 1): Guselkumab (Week 16-52) | Withdrawal and Re-treatment Period- Group 3 (Part 1): Etanercept to Guselkumab (Week 16-52) | Part 2: Guselkumab (Week 0-52) |
|---|---|---|---|---|---|---|---|
| Chronic TonsillitisInfections and infestations | 0/25 | 0/41 | 0/26 | 1/23 | 0/41 | 0/22 | 0/28 |
| Multiple InjuriesInjury, poisoning and procedural complications | 0/25 | 0/41 | 0/26 | 0/23 | 0/41 | 0/22 | 1/28 |
| Radius FractureInjury, poisoning and procedural complications | 0/25 | 1/41 | 0/26 | 0/23 | 0/41 | 0/22 | 0/28 |
| Event | PCP-Group 1 (Part 1): Placebo (Week 0-16) | PCP-Group 2 (Part 1): Guselkumab (Week 0-16) | PCP-Group 3 (Part 1): Etanercept (Week 0-16) | Withdrawal and Re-treatment Period-Group 1 (Part 1): Placebo to Guselkumab (Week 16-52) | Withdrawal and Re-treatment Period-Group 2 (Part 1): Guselkumab (Week 16-52) | Withdrawal and Re-treatment Period- Group 3 (Part 1): Etanercept to Guselkumab (Week 16-52) | Part 2: Guselkumab (Week 0-52) |
|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/25 | 5/41 | 3/26 | 8/23 | 9/41 | 4/22 | 7/28 |
| Covid-19Infections and infestations | 0/25 | 1/41 | 0/26 | 0/23 | 1/41 | 1/22 | 6/28 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/25 | 4/41 | 2/26 | 0/23 | 6/41 | 3/22 | 2/28 |
| AcneSkin and subcutaneous tissue disorders | 0/25 | 1/41 | 0/26 | 0/23 | 2/41 | 0/22 | 3/28 |
| GastroenteritisInfections and infestations | 0/25 | 0/41 | 0/26 | 0/23 | 1/41 | 2/22 | 0/28 |
| HeadacheNervous system disorders | 0/25 | 3/41 | 1/26 | 2/23 | 3/41 | 2/22 | 2/28 |
| FatigueGeneral disorders | 0/25 | 0/41 | 2/26 | 0/23 | 1/41 | 0/22 | 1/28 |
| BronchitisInfections and infestations | 0/25 | 0/41 | 2/26 | 1/23 | 1/41 | 1/22 | 0/28 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/25 | 0/41 | 2/26 | 0/23 | 2/41 | 0/22 | 1/28 |
| Respiratory Tract InfectionInfections and infestations | 0/25 | 0/41 | 0/26 | 0/23 | 0/41 | 0/22 | 2/28 |
| Age, Customized(Participants) | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) | Part 2: Guselkumab (Week 0-16) | Total |
|---|---|---|---|---|---|
| >=6 to <12 years | 10 | 10 | 10 | 0 | 30 |
| >=12 to <18 years | 15 | 31 | 16 | 28 | 90 |
| Sex: Female, Male(Participants) | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) | Part 2: Guselkumab (Week 0-16) | Total |
|---|---|---|---|---|---|
| Female | 13 | 17 | 11 | 11 | 52 |
| Male | 12 | 24 | 15 | 17 | 68 |
| Race/Ethnicity, Customized(Participants) | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) | Part 2: Guselkumab (Week 0-16) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 | 0 | 4 |
| Black or African American | 2 | 1 | 1 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 20 | 36 | 22 | 28 | 106 |
| More than one race | 0 | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
| Other | 1 | 2 | 0 | 0 | 3 |
| Region of Enrollment(participants) | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) | Part 2: Guselkumab (Week 0-16) | Total |
|---|---|---|---|---|---|
| AUSTRALIA | 0 | 1 | 0 | 0 | 1 |
| BELGIUM | 0 | 4 | 5 | 2 | 11 |
| CANADA | 1 | 5 | 1 | 1 | 8 |
| GERMANY | 4 | 4 | 5 | 9 | 22 |
| HUNGARY | 6 | 11 | 4 | 9 | 30 |
| ITALY | 4 | 4 | 1 | 1 | 10 |
| NETHERLANDS | 1 | 2 | 0 | 0 | 3 |
| POLAND | 5 | 7 | 6 | 6 | 24 |
| UNITED STATES | 4 | 3 | 4 | 0 | 11 |
| AgeContinuous(years) | Group 1 (Part 1): Placebo (Week 0-16) | Group 2 (Part 1): Guselkumab (Week 0-16) | Group 3 (Part 1): Etanercept (Week 0-16) | Part 2: Guselkumab (Week 0-16) | Total |
|---|---|---|---|---|---|
| Mean | 12.4 ± 3.63 | 13.4 ± 2.86 | 12.5 ± 3.29 | 15.1 ± 1.59 | 13.4 ± 3.05 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Jul 2023, 60 months.
Results were first posted in Mar 2025, 1 year 8 months after primary completion. A results delay was requested in Jul 2024.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 60 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →